Ecoza (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
Ecoza topical foam, 1% is for topical use only. Ecoza topical foam, 1% is not for oral, ophthalmic, or intravaginal use. Ecoza topical foam, 1% should be applied to cover affected areas once daily for 4 weeks.
Ecoza topical foam, 1% is white to off-white foam supplied in 10g (NDC 23710-100-10) and 70g (NDC 23710-100-75) aluminum pressurized canister. Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze. Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Cont...
www.fda.gov/medwatchEcoza (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
Ecoza topical foam, 1% is for topical use only. Ecoza topical foam, 1% is not for oral, ophthalmic, or intravaginal use.
Ecoza topical foam, 1% should be applied to cover affected areas once daily for 4 weeks.
Foam, 1%. Each gram of Ecoza topical foam, 1%, contains 10 mg of econazole nitrate in a white to off-white foam.
None.
Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Ecoza topical foam or vehicle (246 subjects were exposed to Ecoza topical foam, 1% and 249 were exposed to vehicle). Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms.
Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.
Pregnancy Category C
There are no adequate and well-controlled trials with Ecoza topical foam in pregnant women. Ecoza topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.
It is not known whether econazole nitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when econazole nitrate is administered to a nursing woman. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.
Of the 173 subjects treated with Ecoza topical foam, 1% in the clinical trials, 2 subjects were 12 to 17 years old. In a pediatric maximal use trial, Ecoza topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days [ see Clinical Pharmacology (12.3) ]. The safety findings for subjects 12 to 17 years were similar to those in adult population.
Of the 173 subjects treated with Ecoza topical foam, 1% in the adult clinical trials, 6 subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.
Ecoza (econazole nitrate) topical foam, 1% contains the azole antifungal agent, econazole nitrate in an oil-in-water emulsion base consisting of the following inactive ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant. Each gram of Ecoza topical foam, 1% contains 10 mg of econazole nitrate, USP, in a white to off-white foam. Ecoza topical foam, 1% is alcohol (ethanol)-free and for topical use only.
Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl)methoxy}-2-(2,4-dichlorophenyl) ethyl]-1H-imidazole mononitrate. Econazole nitrate has the molecular formula C 18H 15Cl 3N 2O. HNO 3 and a molecular weight of 444.70. Its molecular structure is as follows:
Ecoza topical foam is an azole antifungal [ see Clinical Pharmacology (12.4) ] .
The pharmacodynamics of Ecoza topical foam, 1% have not been established .
The systemic absorption of Ecoza topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects.
In the adult trial, 19 subjects (male and female) with tinea pedis applied Ecoza topical foam, 1% once daily for 29 days. Subjects applied a mean daily amount of 2.4 g of Ecoza topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean ± SD) showed the time to reach peak plasma concentrations (T max) was 6.8 ± 5.1 h with maximum concentration (C max) of 417 ± 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC (0-12)) was 3440 ± 1920 pg-h/ml.
In the pediatric trial, 18 subjects (male and female ages 12 - 17) with interdigital tinea pedis and positive fungal cultures were treated with Ecoza topical foam, 1% once daily for 4 weeks. Subjects applied a mean daily amount of 3.2 g of Ecoza topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and 7 h and 11 h post-dose. The mean ± SD econazole plasma concentration was 397 ± 289, 534 ± 745 and 575 ± 638 pg/mL at pre-dose and 7 h and 11 h post-dose, respectively.
Mechanism of Action
Econazole nitrate, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the fungistatic activity of econazole. Mammalian cell demethylation is less sensitive to econazole inhibition.
Activity in vitro and in clinical infections
Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections [ see Indications and Usage (1) ].
Trichophyton rubrum
Epidermophyton floccosum
Trichophyton mentagrophytes
Long-term animal studies to determine the carcinogenic potential of Ecoza topical foam have not been performed.
Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation.
In two multi-center, randomized, double-blind, vehicle-controlled clinical trials a total of 505 subjects with interdigital tinea pedis were randomized 1:1 to Ecoza topical foam or vehicle; subjects applied the assigned medication once daily for 4 weeks. The severity of erythema, scaling, fissuring, maceration, vesiculation, and pruritus were graded using a 4-point scale (none, mild, moderate, severe). Subjects had KOH examination and fungal cultures taken to confirm eligibility. A total of 339 subjects with positive fungal cultures were evaluated for efficacy. Efficacy was evaluated on Day 43, 2 weeks post-treatment with treatment success being defined as complete cure (negative KOH and fungal culture and no evidence of clinical disease). The study population ranged in age from 12 to 71 years with 5 subjects less than 18 years of age at baseline. The subjects were 71% male and 51% Caucasian. Table 1 presents the efficacy results for each trial.
| Trial 1 | Trial 2 | |||
|---|---|---|---|---|
| Ecoza topical foam, 1%
N = 82 n(%) | Foam Vehicle
N = 83 n(%) | Ecoza topical foam, 1%
N = 91 n(%) | Foam Vehicle
N = 83 n(%) | |
| Complete cure* | 19 (23.2%) | 2 (2.4%) | 23 (25.3%) | 4 (4.8%) |
| Effective treatment† | 40 (48.8%) | 9 (10.8%) | 44 (48.4%) | 9 (10.8%) |
| Mycological cure‡ | 56 (68.3%) | 13 (15.7%) | 61 (67.0%) | 15 (18.1%) |
Ecoza topical foam, 1% is white to off-white foam supplied in 10g (NDC 23710-100-10) and 70g (NDC 23710-100-75) aluminum pressurized canister.
Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze.
Ecoza topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application.
Contents under pressure. Do not puncture and/or incinerate the containers.
Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty.
Do not store in direct sunlight.
See FDA-approved patient labeling (Patient Information)
The patient should be instructed as follows:
Manufactured in the USA for
Exeltis USA Dermatology, LLC
Florham Park, NJ 07932
PRODERM TECHNOLOGY ®
U.S, Patent 5,993,830
1007501-02
Issued: 07/2016
| Patient Information
ECOZA ® (ee-ko-zah) (econazole nitrate) topical foam, 1% | ||
|---|---|---|
| Important information: Ecoza topical foam is for use on skin only. Do not use Ecoza topical foam in your eyes or vagina. | ||
| What is Ecoza topical foam? Ecoza topical foam is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. | ||
| What should I tell my doctor before using Ecoza topical foam? Before using Ecoza topical foam, tell your doctor about all of your medical conditions, including if you:
| ||
| How should I use Ecoza topical foam? See the detailed Instructions for Use for information about how to use Ecoza topical foam.
| ||
What should I avoid while using Ecoza topical foam?
| ||
| What are the possible side effects of Ecoza topical foam? Ecoza topical foam may cause skin reactions at the treatment site. Tell your doctor if you have any skin reactions on the areas of your skin treated with Ecoza topical foam. These are not all the possible side effects of Ecoza topical foam. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How should I store Ecoza topical foam?
| ||
| General information about the safe and effective use of Ecoza topical foam Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your doctor or pharmacist for information about Ecoza topical foam that is written for health professionals. Do not use Ecoza topical foam for a condition for which it was not prescribed. Do not give Ecoza topical foam to other people, even if they have the same symptoms that you have. It may harm them. | ||
| What are the ingredients in Ecoza topical foam? Active ingredient: econazole nitrate USP Inactive Ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant. Manufactured for Exeltis USA Dermatology, LLC Florham Park, NJ 07932 For more information call Exeltis USA, Inc. at 1-877-324-9349. | ||
| This Patient Information has been approved by the U.S. Food and Drug Administration. | Issued:07/2016 | 1007501-02 |
| Important information: Ecoza topical foam is for use on skin only. Do not use Ecoza topical foam in your eyes or vagina. |
Parts of Ecoza topical foam Canister. (See Figure A)
 |
| Figure A |
How to apply Ecoza topical foam:
| Step 1: | Before you apply Ecoza topical foam, shake the Ecoza topical foam canister for about 5 seconds. |
| Step 2: | Remove the cap and turn the Ecoza topical foam canister upside down over the palm of your hand. |
| Step 3: | Press down firmly on the actuator until there is a small amount of foam about the size of a golf ball in the palm of your hand. (See Figures B and C) |
 |  |
| Figure B | Figure C |
| Step 4: | Use your finger-tips to scoop up small amounts of Ecoza topical foam and apply to the affected skin areas on your feet. Gently rub the foam into the skin. (See Figure D) |
| |
| Figure D | |
| Step 5: | You should apply Ecoza topical foam to your toes, to the spaces between your toes, and to the surrounding areas 1 time a day for 4 weeks or as prescribed by your doctor. |
| Step 6: | Replace the cap. Wash your hands after applying Ecoza topical foam. |
How should I store Ecoza topical foam?
Keep Ecoza topical foam and all medicines out of the reach of children.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Manufactured for Exeltis USA Dermatology, LLC Florham Park, NJ 07932
Issued: 07/2016
NDC 23710-100-70
ecoza™
(econazole nitrate)
topical foam, 1%
For Topical Use Only
Not for ophthalmic, oral or intravaginal use.
Keep Out of Reach of Children
Rx Only
Net Wt 70g
Exeltis
Rethinking healthcare
NDC 23710-100-70
ecoza™
(econazole nitrate)
topical foam, 1%
For Topical Use Only
Not for ophthalmic, oral
or intravaginal use.
Keep Out of Reach of Children
Rx Only
Net Wt 70g
Exeltis
Rethinking healthcare
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 23710-100-70 | GM - Gram | 23710-100 | acd7f09c-4208-4267-abae-3dd0403a5986 | 1 | 2014-01-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ECONAZOLE NITRATE | ACTIVE INGREDIENT | H438WYN10E | 4 | |
| ECONAZOLE | ACTIVE MOIETY | 6Z1Y2V4A7M | 4 | |
| BUTANE | INACTIVE INGREDIENT | 6LV4FOR43R | 4 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 4 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 4 | |
| POVIDONE K29/32 | INACTIVE INGREDIENT | 390RMW2PEQ | 4 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 4 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 4 | |
| TROLAMINE | INACTIVE INGREDIENT | 9O3K93S3TK | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 23710-100 | 23710-100-70 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| DIMETHICONE | 92RU3N3Y1O | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| POLYSORBATE 20 | 7T1F30V5YH | IACT |
| POVIDONE K30 | U725QWY32X | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| STEARIC ACID | 4ELV7Z65AP | IACT |
| TROLAMINE | 9O3K93S3TK | IACT |
| WATER | 059QF0KO0R | IACT |
| BUTANE | 6LV4FOR43R | IACT |
| ECONAZOLE NITRATE | H438WYN10E | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | SOAP / TOPICAL | 0.08 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / DENTAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / INTRAVENOUS | 5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CREAM / VAGINAL | 1088 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | GEL, METERED / TOPICAL | 20 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | AEROSOL, METERED / RECTAL | ADJ PH | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYRUP / ORAL | 5700 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | EMULSION / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CLOTH / TOPICAL | 0.03 mg/mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | TABLET, FILM COATED / ORAL | 0.35 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SWAB / TOPICAL | 34.6 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / TOPICAL | 0.75 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | GEL / TRANSDERMAL | 6 mg | ||
| BUTANE | BUTANE | 6LV4FOR43R | AEROSOL, FOAM / RECTAL | 12 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / OPHTHALMIC | 1.5 %w/v | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | LOTION / TOPICAL | 80 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | SOAP / TOPICAL | 6 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / RECTAL | 27 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.02 %w/v | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | CAPSULE / ORAL | 563 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | POWDER / TOPICAL | 0.02 mg/mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL / TOPICAL | 19.2 %w/w | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SUSPENSION / AURICULAR (OTIC) | 0.1 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION, EXTENDED RELEASE / ORAL | 1000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | SPONGE / TOPICAL | 11 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM, AUGMENTED / TOPICAL | 8 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, DELAYED RELEASE / ORAL | 1.7 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N205175-001 | ECOZA | ECONAZOLE NITRATE | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N205175-001 | ECOZA | 1% | AEROSOL, FOAM / TOPICAL | RLD, RS | 2013-10-24 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N205175-001 | 10071054 | 2031-08-08 | Drug product | 2018-09-27 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 269f9ece-dea7-d97c-e063-6394a90a9783 | 998798bc-5c64-4e4c-a0d6-925278ff76a4 | 2024-11-11 | Warnings, Adverse reactions | 998798bc-5c64-4e4c-a0d6-925278ff76a4 |
Adverse event summaries are temporarily unavailable. Other product information remains available.
